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ABSTRACT: 
Medical ghostwriting, while in and of itself ethical, is used for unethical purposes. Many 
ghostwritten articles are used by pharmaceutical companies to present manipulated data in 
order to increase sales. In response to the rise of ghostwritten articles responses such as 
stricter laws and publishing regulations are proposed. It is believed that the proposed laws and 
regulations will return trust to the medical field. 
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 As medical ghostwriting is becoming more widespread and prevalent it has become 
a topic subject to much discussion. Much of the discussion about medical ghostwriting 
addresses the ethical implications of the practice. Literature, including books, scientific 
articles, and newspaper articles, were reviewed alongside several examples of known 
ghostwritten articles. 
 The ghostwritten articles covered were the Vioxx VIGOR trial (Bombardier et al., 
2000) and the Paroxetine 352 study (Nemeroff et al., 2001). Responses to the two articles 
were reviewed alongside literature review articles detailing finances, ethical 
considerations, publishing regulations, and laws pertaining to ghostwriting. 
 It was determined that while ghostwriting isn’t unethical the use of medical 
ghostwriting is. Pharmaceutical companies use ghostwriting in an unethical manner to 
manipulate the results of studies and increase profits. This causes a loss of trust in the 
medical field by allowing harmful drugs to be prescribed and preventing the best possible 
care from being received by patients. To combat this and help regain the lost trust stricter 
publishing regulations and laws have been proposed. 
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1. INTRODUCTION: 
 
 The prevalence of medical ghostwriting is a large issue appearing in biomedical 
literature. While much has been done to address the issue it still raises many ethical 
questions. Another problem presented by medical ghost writing is the question of trust in 
the medical field, especially as there is relatively little regulation of ghostwriting and only 
loose legal ramifications. 
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2. METHODS: 
 
 Literature on the topic of medical ghostwriting was found and reviewed to create a 
clearer picture of the issue and potential solutions. Several books on the topic were used 
as well as journal articles found through databases such as PubMed and Google Scholar 
and articles used as references in previously found works.  
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3. BACKGROUND: 
 
 Within the field of technical writing exists a practice called ghostwriting. 
Ghostwriting is the act one author of writing a piece which other authors take credit for. 
While much of popular ghostwriting is speech writing for politicians or media 
personalities, the practice also takes place in scientific journals. The act of ghostwriting, 
especially in the sciences, is done to the extent that guides such as 101 Ways to Find Six-
Figure Medical or Popular Ghostwriting Jobs & Clients (Hart, 2006), are widely sold. Other 
literature also addresses ghostwriting in terms of ethics (Stichler, 2004) and in law 
(Dukes, 2014). 
 The widespread practice of ghostwriting has even pervaded sensitive genres such 
as medicine and more specifically pharmaceuticals. Due to the sensitive nature of the 
topic there has been much written on medical ghostwriting and the pharmacy industry 
itself. This writing comes in many forms such as journal articles, books , and newspaper 
articles. Ethicist Carl Elliot’s book on the topic, White Coat Black Hat: Adventures on the 
Dark Side of Medicine views the ethics of the pharmaceutical industry from several 
standpoints. Elliot looks in depth at pharmaceutical test subjects, drug reps, doctors, and 
ghostwriters. In the case of ghostwriting Elliot uses personal interviews and scholarly 
articles to delve into the ethics of ghostwriting. While Elliot’s position on the topic is left 
ambiguous much of the evidence he presents paints a picture of ghostwriting being an 
unethical soul sucking profession. This view comes from the personal accounts of both 
current and former ghostwriters as well as medical literature. 
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One of the most prominent examples of medical ghostwriting, and the main article 
mentioned by Elliot, is the Vioxx VIGOR study released in 2000. Vioxx was a drug 
marketed by the company Merck in the early 2000’s which was pulled from the shelves in 
2004 after many negative side effects, such as heart failure, were revealed. The 
controversy stemmed from the fact that the VIGOR study authored, on paper, by 
Bombadier et al. in 2000 and published in the prestigious New England Journal of 
Medicine (NEJM) was found to be ghostwritten and contained false information. Upon 
Vioxx’s removal from the market it was revealed that the “authors” of the VIGOR study 
were consultants paid by Merck who were either completely or mostly uninvolved with 
the study or writing of the article (Krumholz et al., 2007). The omitted and falsified 
information in the VIGOR study caused a public outcry aimed mostly at the NEJM for not 
realizing the article was written by Merck itself (Armstrong, 2006). 
 While Vioxx is a prime example of ghostwriting many others exist. Mixed sciences 
magazine The Scientist published an article overviewing another high profile ghostwriting 
incident in a 2009 article by Bob Grant (Grant, 2009). The article highlights a situation in 
which Merck paid scientific publisher Elsevier to publish a special issue containing six 
fake articles. By themselves the six articles showed no corporate sponsorship and were 
written to seem like legitimate journal articles. Further research disclosed that Merck 
both funded and wrote the six articles for the purpose of increasing sales. Another major 
example of ghostwriting is the Paroxetine 352 bipolar trial (Nemeroff et al., 2001). 
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 Like the Vioxx VIGOR study the Paroxetine 352 trial was an industry sponsored 
study published in a major medical journal. In 2001 the American Journal of Psychiatry 
published the study which contained no indication of industry sponsorship. In 2012 
Amsterdam and McHenry disclosed the ghostwritten nature of the study (Amsterdam, 
2012). The Paroxetine 352 study, funded by GlaxoSmithKline, reported positive results 
when the trials showed that there was no difference between paroxetine and placebos in 
the treatment of bipolar depression. 
 While there are a significant number of ghostwritten articles in circulation at 
present much of the literature on ghostwriting is written in response to ghostwritten 
articles. The response articles cover material ranging from literature reviews to ethics 
and legality. Many of the review articles are like the aforementioned Krumholz and 
Amsterdam articles, but some review the prevalence of ghostwriting as a whole. While 
considering all publication types a sample of 848 articles were reviewed with nearly 100 
showing signs of ghostwriting (Stretton, 2014). Another review study was done focusing 
on high impact journals published by Elsevier and Wiley-Blackwell. This study consisted 
of 399 articles from 15 top rated journals and it found that only 10% of the journals had 
an explicit definition of ghostwriting and less than 6% had detection and response 
procedures (Bosch, 2013). The article goes on to state that the low scores indicate that 
either journals don’t view ghostwriting as a serious problem or they are influenced by 
industry payments. A consistent statement from both of the literature review articles is 
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the need for a clear definition of ghostwriting to be given by publishers as well as explicit 
ghostwriting response policies. 
 Much of the remaining ghostwriting literature focuses on the ethics of ghostwriting 
as well as the ethics of publishing ghostwritten articles. Carl Elliot’s book White Coat 
Black Hat devotes a chapter to the ethics of ghostwriting and the ethicists involved in 
overseeing the journal review boards. Elliot interviews ethicists and does an overview of 
many of the review boards. Elliot places the review boards into two categories: non-profit 
and for profit. The non-profit boards are generally more prestigious and harder to get 
approved by. On the other hand the for profit boards show a correlation between cost, 
prestige, and approval rate. Many of the review boards are private and don’t release the 
basis of their decisions. 
 Beyond the ethical review boards many biomedical journals require published 
work to follow certain guidelines. One of the best known sets of guidelines is the AMA 
Manual of Style, which entering its tenth edition addresses both ethical and legal issues in 
publishing (Christiansen, 2008). The AMA Manual of Style addresses topics such as 
authorship and disclosure of conflicts of interest. While much of this information is for 
formatting the journal it is also used to help combat ghostwritten articles. 
 An article focusing on ethics was written by Almassi in 2014. In the article Almassi 
argues that ghostwriting, while not outright plagiarism is a type of fraud. This fraud 
doesn’t necessarily come from bad science but instead from a lack of credibility and trust. 
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With little to no corporate interest disclosure ghostwritten articles erode the trust that is 
implicitly placed in the healthcare system. The erosion of trust comes from the idea that 
articles are written as a way to increase corporate profits as opposed to having the health 
of the people in mind. In addition ghostwriting causes a loss of credibility to both the 
article and the publishing journal. The loss of credibility for both the article and 
publishing journal comes from the fact that the medical writer, who is not mentioned in 
the article, may have had little to no contact with the research team or primary author 
and just as importantly there is no evidence that proper scientific procedure is followed. 
Another article focusing on ghostwriting viewed ethics from the point of view of 
publishers (Stichler, 2014). Stichler outlines a code of conduct for reporting research in 
journals as well as the ethics involved in the research and writing. Some of the points 
which Stichler outlines are a clear dissemination of data throughout the entirety of the 
published article, transparency of authors and findings, and following the guidelines of 
the Committee on Publication Ethics, founded in 1997. Stichler also mentions that many 
professional associations and universities have developed their own code of ethics which 
become part of published articles. 
 Many other articles comment on the ethics of ghostwriting from different angles. 
Aside from standards of professionalism and published articles on the ethics of 
ghostwriting, the practice has been examined on the basis of financial analysis as well as 
the scrutiny of the law. While these are important lens through which to evaluate 
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ghostwriting they are seen to a lesser degree than the ethics of professionalism and 
publishing and this is in part due to the sensitivity of the topic. 
 In 2003, Bekelman conducted a study into financial conflicts of interest in 
biomedical research. The article brings to light the fact that over a twenty year period 
(1980-2000) industry’s share of investment in biomedical research increased by nearly 
30%, making industry the largest investor. The problem which arose from this is that 
many medical journals do not require financial interests to be disclosed within the article. 
The study explored this fact by analyzing 37 articles for financial conflicts of interest as 
well as analyzing past studies on financial conflicts of interest. The analysis suggested 
that about 25% of research studies receive industry funding and nearly 33% of lead 
authors of research articles have industry ties either from direct payments or through 
their universities. While the study initially seemed to imply that the industry-sponsored 
studies showed promising results, further analysis proved that industry-sponsored 
research articles showed delays in publishing as well as a higher likelihood of reporting 
altered or misinterpreted data. Out of the 37 articles analyzed, Bekelman found that only 
eight addressed financial conflicts of interest and that less than half of peer-reviewed 
journals have financial disclosure policies. Due to the sensitive nature of finances the 
study suggests that close scrutiny of research articles is advisable as well as reform to 
disclosure laws and regulations. 
 In terms of laws ghostwriting falls into a grey zone. While many ethicists view 
ghostwriting as fraud it is rarely pursued in court to establish legal precedent. Much of 
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the law enforcement in cases of ghostwriting comes from the settlement of charges 
levelled against the industry sponsors (Dukes, 2014). One such instance of this was after 
the Vioxx VIGOR study was shown to be ghostwritten. As part of the settlement, Merck 
was obliged to have the author of an article be the main contributor instead of a 
figurehead. While Dukes’ book just does an overview of ghostwriting in the law, other 
literature urges action. 
 Many ethicists believe that ghostwriting should fall under the federal False Claims 
Act, which protects against fraud and slander (Bosch, 2012). The reasoning behind this is 
that ghostwritten articles may contain false or manipulated data which may influence the 
judgment of doctors and cause patients harm or at least prevent them from receiving the 
best possible treatment. Bosch’s article presents several legal remedies for medical 
ghostwriting. By claiming that ghostwriting is a form of fraud it will not be protected as 
free speech as the US Supreme Court has ruled that the First Amendment does not shield 
fraud. Bosch also argues that ghostwritten articles should be liable under the Anti-
Kickback Statute used to protect Medicare and Medicaid against inappropriate use. This 
would make guest authors and physicians hired to sign off on studies they didn’t work on 
legally liable and subject to up to $25,000 in fines and five years of imprisonment for 
harmful unethical articles. Bosch claims that these legal proposals will help to prevent 
medical ghostwriting as well as help restore credibility to medical journals and 
professionals. 
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4. DISCUSSION: 
 
 Ghostwriting is a tool, and like all tools it is only as ethical as its user. In the case of 
medical ghostwriting it is more unethical than not, unlike political ghostwriting which 
has become standard practice. Ghostwriting is used by the biomedical industry to 
manipulate data and increase profits which is decidedly unethical. 
 The unethical nature of medical ghostwriting comes in part from the fact that 
ghostwritten articles may not have the public’s best interest at heart. For example the 
2000 Vioxx Vigor study and the 2001 Paroxetine 352 study were ghostwritten. Both 
studies posed false claims based on manipulated data to improve the sale of the 
respective drug. The false information created a situation in which many doctors, who 
use medical journals to learn about the next big therapeutic advance, inadvertently 
prescribed a harmful and/or inferior medicine. The fact that falsified information is being 
fed to the very people we trust to keep us healthy is unnerving and what’s worse is that it 
is for profit. What’s more surprising is the relative leniency that the reported 25% of 
studies (Bekelman, 2003) that are influenced by money from the pharmaceutical 
companies get in the court of law. 
 With no laws currently policing medical ghostwriting the pharmaceutical 
companies are only subject to paying civil reparations claims and other small settlements 
out of court. In the case of Vioxx, besides paying reparations Merck agreed to have future 
articles primary authors be the main contributors to research articles (Dukes, 2013), a 
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small price to pay when you can buy someone’s word. To combat the relatively low 
punishment rate harmful ghostwriting should be considered fraud and subject to the 
same punishments as someone who tries to abuse programs such as Medicare or an 
industry making false claims about its product. Of course all this requires that the 
ghostwritten article gets published in the first place. 
 To help stem the tide of unethically driven medical ghostwriting, articles must meet 
a series of requirements set by the prospective journal as well as gain the approval of 
several institutional review boards. Many journals have a list of standards and practices 
that an article must meet before being published, such as the AMA manual of style. While 
these standards are meant to inhibit the inclusion of false information and bad science 
only in recent years have they begun to look for ghostwriting. To combat ghostwritten 
articles many journals have started to include standards asking for transparency of 
authors and conflicts of interest, the problem being that transparency is asked for but not 
required. The institutional review boards are a system of peer review that an article must 
go through before being considered for publishing. Like the various journals’ standards of 
practice the review boards are meant to prevent false information and bad science from 
being published. Each journal requires a set number of approvals from the review boards 
before an article can be published. While this was set up as a safeguard, ways around it 
have been found. While many ethics-driven review boards exist, they are vastly 
outnumbered by for profit review boards. The for profit boards will review an article for 
a fee and are not legally required to explain their judgement on a particular article. If the 
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for profit boards were required to explain their reasoning on the approval of an article it 
would help curb the number of ghostwritten articles being approved purely because of 
money. 
 The fact that harmful ghostwritten articles can get published for money instead of 
merit creates a bad situation in the medical field. If the information given to our doctors 
can be falsified how can the public be expected to intrinsically place their trust in 
medicine? Medical ghostwriting has eroded the trust that the public has placed in doctors 
as well as the trust that many doctors place in medical journals. In the eyes of the public 
the concept of medical ghostwriting raises the question of whether or not the best 
possible care is being received because how can one know that their doctor isn’t getting 
paid to prescribe, or not prescribe, a certain drug. As for the professional side doctors are 
losing trust in medical journals. If the pharmaceutical companies can pay to get an article 
published or authored by key opinion leaders then how can doctors trust the medical 
journals? Since medicine is not like politics this erosion of trust is a significant source of 
damage to the field and measures should be taken to rebuild this trust. Many of the 
suggestions listed above on laws and regulations would help to return trust to the 
medical field. 
 Another erosion of trust comes from the fact that medical ghostwriting is an open 
secret. That is, the profession knows many people participate in ghostwriting but it is 
purposefully overlooked as a secret. This open secret becomes visible through an analysis 
of studies and the responses given to ghostwriting. Various studies show that 
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ghostwritten articles are still being published despite the fact that journals know them to 
be ghostwritten. Another way this practice is enabled is through the lack of a centralized 
standard for publication. If there was a standard which every journal kept requiring 
transparency in both authorship and discussed financial conflicts of interest, much of the 
professional distrust in the medical field would be alleviated. 
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5. CONCLUSION: 
 
 The act of ghostwriting is not ethically wrong but how medical ghostwriting is used 
is. By ghostwriting articles pharmaceutical companies create big scandals, as in the cases 
of Vioxx and Paroxetine, which stemmed from the want of profits. This profit hungry 
attitude has eroded public trust in the medical community and brought both physical and 
financial harm to various individuals. 
 To prevent ghostwriting from further eroding public trust many ethics committees 
and review boards have come into being. The for profit nature of many of these 
institutions show that greater regulations should be placed on medical articles. The 
publishing companies should require articles to have full disclosure with regards to 
corporate sponsorship and conflicts of interest. Also publishers should require 
transparency with authorship. Legally ghostwritten articles found to be showing false or 
manipulated data which causes harm should be considered fraud. This will make both 
authors and sponsors legally responsible for their work. Those suggestions should curb 
the unethical use of medical ghostwriting and work to rebuild any lost trust in the 
medical field. 
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